Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes by Smith, Helen J. & Tisdale, Michael J.
Signal transduction pathways involved in proteolysis-inducing
factor induced proteasome expression in murine myotubes
HJ Smith1 and MJ Tisdale*,1,2
1Pharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, UK
The proteolysis-inducing factor (PIF) is produced by cachexia-inducing tumours and initiates protein catabolism in skeletal muscle.
The potential signalling pathways linking the release of arachidonic acid (AA) from membrane phospholipids with increased
expression of the ubiquitin–proteasome proteolytic pathway by PIF has been studied using C2C12 murine myotubes as a surrogate
model of skeletal muscle. The induction of proteasome activity and protein degradation by PIF was blocked by quinacrine, a
nonspecific phospholipase A2 (PLA2) inhibitor and trifluroacetyl AA, an inhibitor of cytosolic PLA2. PIF was shown to increase the
expression of calcium-independent cytosolic PLA2, determined by Western blotting, at the same concentrations as those inducing
maximal expression of 20S proteasome a-subunits and protein degradation. In addition, both U-73122, which inhibits agonist-
induced phospholipase C (PLC) activation and D609, a specific inhibitor of phosphatidylcholine-specific PLC also inhibited PIF-
induced proteasome activity. This suggests that both PLA2 and PLC are involved in the release of AA in response to PIF, and that this
is important in the induction of proteasome expression. The two tyrosine kinase inhibitors genistein and tryphostin A23 also
attenuated PIF-induced proteasome expression, implicating tyrosine kinase in this process. PIF induced phosphorylation of p44/42
mitogen-activated protein kinase (MAPK) at the same concentrations as that inducing proteasome expression, and the effect was
blocked by PD98059, an inhibitor of MAPK kinase, as was also the induction of proteasome expression, suggesting a role for MAPK
activation in PIF-induced proteasome expression.
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Loss of muscle mass is a debilitating and life-threatening feature of
cancer cachexia, as well as a number of other catabolic conditions
such as sepsis, burn injury, metabolic acidosis, severe trauma and
denervation atrophy. In all these conditions, muscle wasting is due
to accelerated muscle protein breakdown, combined with
decreased protein synthesis. The major proteolytic pathway
considered to be responsible for the increased protein catabolism
in skeletal muscle is the ubiquitin–proteasome proteolytic path-
way (Lecker et al, 1999). In this process, proteins are marked for
degradation by attachment of a polyubiquitin chain through a
series of enzymes (E1, ubiquitin-activating enzyme; E2, ubiquitin-
conjugating enzyme; E3, ubiquitin–protein ligase) and are
hydrolysed to peptides within a large (2000 kDa) 26S proteasome
in a process that is ATP dependent. An increased expression of
proteasome subunits and E214k has been observed in the
gastrocnemius muscle of cachectic mice (Lorite et al, 1998) and
rats (Temparis et al, 1994), suggesting these elements to be
important in the increased protein degradation, although recent
studies (Bodine et al, 2001) suggest that E3 may be rate limiting in
ubiquitin conjugation.
We have isolated and characterised a sulphated glycoprotein
(Todorov et al, 1996a), which initiates catabolism of skeletal
muscle proteins both in vitro (Smith et al, 1999) and in vivo (Lorite
et al, 1998), and for this reason has been called the proteolysis-
inducing factor (PIF). PIF is produced by the cachexia-inducing
murine MAC16 tumour (Todorov et al, 1996a) as well as murine
colon 26, clone 20 variant, which induces cachexia, but not by
clone 5, which does not induce cachexia (Hussey et al, 2000).
Proteolysis-inducing factor is produced by human carcinomas of
various types (Cariuk et al, 1997) and has been correlated with a
significantly greater total weight loss and rate of weight loss in
patients with pancreatic carcinoma (Wigmore et al, 2000). The
induction of protein catabolism by PIF was shown to be due to
upregulation of the ubiquitin–proteasome pathway both in vivo
and in vitro (Lorite et al, 2001), suggesting a direct effect of PIF on
this pathway.
Initial studies showed that protein catabolism induced by PIF
was associated with the release of arachidonic acid (AA) and the
conversion to eicosanoid metabolites of which 15(S)-hydroxyei-
cosatetraenoic acid (15(S)-HETE) was considered to play a central
role in protein degradation (Smith et al, 1999). However, the
mechanism by which this occurred and the relationship with
proteasome and E214k expression was not determined. The most
likely mechanism would involve phospholipase A2 (PLA2) acting
on phospholipids releasing AA and a lysophospholipid, or by
phospholipase C (PLC) with the formation of a diacylglycerol
(DAG), followed by DAG lipase forming AA. The products of theReceived 6 May 2003; revised 20 August 2003; accepted 26 August 2003
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PLC reaction (Nakamura and Nishizuka, 1994) as well as AA and
lipoxygenase metabolites (Fan et al, 1990) are signalling molecules,
which activate the protein kinase C (PKC) family of serine/
threonine kinases, which we have shown (unpublished results) to
act as intracellular signals of PIF action on the proteasome. The
current study investigates the role of PLA2 and PLC on PIF-
induced proteasome expression as well as on potential substrates
for PKC using C2C12 myotubes, which we have previously shown
(Gomes-Marcondes et al, 2002) to be a good model for studying
PIF action on the proteasome.
MATERIALS AND METHODS
Materials
Fetal calf serum (FCS), horse serum (HS) and Dulbecco’s modified
Eagle’s medium (DMEM) were purchased from Life Technologies
(Paisley, UK). Mouse monoclonal antibody to 20S proteasome
subunits a1, 2, 3, 5, 6 and 7 (clone MCP 231) were purchased from
Affiniti Research Products (Exeter, UK), and rabbit polyclonal
antisera to the ubiquitin-conjugating enzyme (E214k) was a gift
from Dr Simon Wing, McGill University, Montreal, Canada. The
antibody recognises both isoforms of E214k encoded by HHR6A
and HHR6B (Rajapurohitam et al, 1999). The HHR6B gene
encodes the isoform for which mRNA levels increase in atrophying
muscles. The antibody detected E214k as an Mr 17 000 band.
Mitogen-activated protein kinase (MAPK) proteins and their
phosphorylated (active) forms were detected with anti-extracel-
lular signal-regulated kinase (ERK)1 and 2 [pTpY185/187] nonpho-
sphospecific and phosphospecific rabbit polyclonal antisera
(Biosource International, Belgium). Rabbit polyclonal antisera to
PLA2, Type V1 was purchased from Calbiochem, Nottingham, UK.
Sheep anti-mouse and goat anti-rabbit antisera were purchased
from Dako Ltd (Cambridge, UK), while the b-tubulin mouse
monoclonal antibody was obtained from Calbiochem, Nottingham,
UK. The following inhibitors were also purchased from Calbio-
chem: quinacrine dihydrochloride, trifluoroacetylarachidonic acid,
U73122, D609, genistein, tryphostin A23 and PD 98059.
Cell culture
C2C12 myoblasts were grown in DMEM supplemented with 10%
FCS, glutamine and 1% penicillin–streptomycin in a humidified
atmosphere of 10% CO2 in air at 371C. Myotubes were formed by
allowing confluent cultures to differentiate in DMEM containing
2% HS, with medium changes every 2 days.
Purification of PIF
PIF was purified from solid MAC16 tumours excised from mice
with a weight loss between 20 and 25%. Tumours were
homogenised in 10mM Tris-HCl, pH 8.0 containing 0.5mM
phenylmethylsulphonyl fluoride, 0.5mM EGTA and 1mM dithio-
threitol at a concentration of 5ml g1 tumour. The supernatant
obtained after ammonium sulphate (40%wv1) was subjected to
affinity chromatography using an anti-PIF monoclonal antibody
coupled to a solid matrix as described (Todorov et al, 1996a). The
immunogenic fractions were concentrated and used for further
studies. The only contaminant was albumin (Todorov et al, 1996b)
and the PIF was used without further purification.
Measurement of proteasome activity
The ‘chymotrypsin-like’ enzyme activity of the proteasome was
measured using the fluorogenic substrate suc-LLVY-aminomethyl
coumarin (0.1mM) essentially according to the method of Orino
et al (1991). Myotubes were washed in ice-cold phosphate-buffered
saline (PBS) and sonicated in 20mM Tris-HCl, pH 7.5, 2mM ATP,
5mM MgCl2 and ImM dithiothreitol at 41C. The supernatant
formed by centrifugation at 15 000 r.p.m. for 10min at 41C was
analysed for ‘chymotrypsin-like’ activity using a Microplate
Spectrofluorimeter (SPECTR max, Molecular Devices, CA, USA).
Results were calculated as activity mg protein1min1. Protein
degradation in the presence of PIF was determined as previously
described (Gomes-Marcondes et al, 2002).
Western blot analysis
Samples of cytosolic protein (2.5–5 mg) were resolved on 10%
sodium dodecylsulphate–polyacrylamide gels (SDS–PAGE) and
transferred onto Hybondt ECLt nitrocellulose membranes
(Amersham, UK), which had been blocked with 5% Marvel in
Tris-buffered saline, pH 7.5, at 41C overnight. The primary
antibodies were used at a dilution of 1 : 40 (b-tubulin); 1 : 100
(E214k); 1 : 500 (anti-ERK1 and 2) or 1 : 1500 (anti-20S proteasome),
while the secondary antibodies were used at a dilution of 1 : 2000.
Incubation was carried out for 2 h at room temperature and
development was by enhanced chemiluminescence (Amersham
UK). Loading was quantitated either by b-tubulin or by a parallel
gel, which was stained with Coomassie brilliant blue.
Statistical analysis
Results are expressed as means7s.e.m. Differences were deter-
mined by one-way ANOVA followed by the Tukey–Kramer
multiple comparison test.
RESULTS
The effect of quinacrine, a nonspecific PLA2 inhibitor on
proteasome functional activity (‘chymotrypsin-like’ enzyme activ-
ity), in the presence of PIF is shown in Figure 1A. As previously
reported (Gomes-Marcondes et al, 2002), PIF produced a
significant increase in proteasome activity at concentrations
between 2 and 10 nM, with a peak of activity at 4 nM, while both
higher and lower concentrations had no effect. At a concentration
of 5 mM, quinacrine completely attenuated the increase in
‘chymotrypsin-like’ enzyme activity in the presence of PIF
(Figure 1A), as did the cytosolic PLA2 inhibitor trifluroacetyl AA
(Figure 1B). This might be expected, since cytosolic PLA2 exhibits
a high selectivity towards the cleavage of unsaturated fatty acids
and in particular AA (Glasser et al, 1993). Both quinacrine and
trifluroacetyl AA also attenuated the PIF-induced increase in
protein degradation (Figure 1C). Trifluoroacetyl AA also attenu-
ated the increase in 20S proteasome expression in the presence of
PIF (Figure 2A) and the increase in calcium-independent cytosolic
PLA2 (iPLA2) (Figure 2B) as detected by Western blotting.
The PIF-induced increase in ‘chymotrypsin-like’ enzyme activity
was also inhibited by U-73122 (Figure 3A), which inhibits agonist-
induced PLC activation (Yule and Williams, 1992), and D609
(Figure 3B), a selective inhibitor of phosphatidylcholine (PC)-
specific PLC (Sauer et al, 1984). These results suggest that both
PLA2 and PLC are involved in the hydrolysis of AA from
membranes of muscle cells in response to PIF, and that this is
important in proteasome expression.
If PLC is involved in PIF-induced proteasome induction, this
suggests that PKC may also be required for intracellular signal
transduction. We have previously shown (unpublished results)
that PKC is involved in PIF-induced proteasome expression and
therefore the effect of two tyrosine-kinase inhibitors genistein and
tryphostin A23 on PIF-induced ‘chymotrypsin-like’ enzyme
activity was determined (Figure 4). Both genistein at a concentra-
tion of 100 and 300 mM (Figure 4A) and tryphostin A23, also at a
concentration greater than 100mM (Figure 4B), completely
attenuated the PIF-induced increase in proteasome activity. These
PIF-induced proteasome expression
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results suggest that protein tyrosine kinase is also involved in PIF-
induced proteasome expression.
Activation of PKC has been shown to activate the ERK and
subsequently MAPK (Toker, 1998). To investigate a role for MAPK
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Figure 1 Effect of PIF concentration on the chymotrypsin-like enzyme
activity of the proteasome in C2C12 myotubes in the absence ( ) and
presence (’) of (A) quinacrine (5 mM) or (B) trifluoroacetyl AA (20 mM).
(C) The effect of quinacrine (5 mM) (&), trifluoroacety l AA (20 mM) (’)
and PD98059 (10 mM) (&) on protein degradation determined by the
release of phenylalanine as previously described (Gomes-Marcondes et al,
2002) in murine myotubes in the presence of PIF. The experiments were
repeated three times (n¼ 9). Differences from control are indicated as a,
Po0.01 and b, Po0.001, while differences from those in the absence of
the inhibitors are indicated as c, Po0.0001. The inhibitors were added to
the cells 2 h prior to PIF.
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Figure 2 Western blot of soluble extracts of C2C12 myotubes treated
with 0 (lanes 1 and 7); 1.0 (lanes 2 and 8); 2.1 (lanes 3 and 9); 4.2 (lanes 4
and 10); 10 (lanes 5 and 11) or 20 nM PIF (lanes 6 and 12) in the absence
(lanes 1–6) or after 2 h pretreatment with trifluoroacetyl AA (20 mM)
(lanes 7–12). Bands were detected using either antibody to 20S
proteasome a-subunits (A), iPLA2 (B) or b-tubulin (C). The blots shown
are representative of at least three separate experiments.
1800
1600
1400
1200
1000
800
600
400
200
0
0 1 2.1 4.2 10 20
PIF nM
0 1 2.1 4.2 10 20
PIF nM
2500
2000
1500
1000
500
0
%
 C
on
tro
l
%
 C
on
tro
l
A
B
b
b
b
c
c
b
c
Figure 3 Effect of PIF concentration on the chymotrypsin-like enzyme
activity of the proteasome in C2C12 myotubes in the absence ( ) or
presence (’) of U7311 (5mM) (A) or D609 (200 mM) (B). The inhibitors
were added to the cells 2 h prior to PIF. The experiment was repeated
three times (n¼ 9). Differences from the control are indicated as b,
Po0.001, while differences from those in the absence of inhibitors are
indicated as c, Po0.001.
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in PIF-induced proteasome expression, the effect of the selective
and cell-permeable inhibitor of MAP kinase kinase (MEK)
PD98059 (Ku¨ltz et al, 1998) was investigated. PD98059 attenuated
the PIF-induced increase in ‘chymotrypsin-like’ enzyme activity
(Figure 5A), 20S a-subunit expression (Figure 5B) and E214k
(Figure 5C). As shown in Figure 6A, PIF induced phosphorylation
of p44/42 MAPK, while the total MAPK remained unchanged
(Figure 6B). The concentration of PIF inducing a maximum
phosphorylation of p44/42 MAPK (Figure 6A) (4.2 nM) was the
same as that inducing proteasome expression and E214k (Figure 5).
PD98059 completely blocked PIF-induced p44/42 MAPK activation
(Figure 6A) as well as proteasome expression (Figure 5), confirm-
ing a role for MAPK activation in PIF-induced proteasome
expression.
DISCUSSION
Using murine myoblasts as a surrogate model of skeletal muscle,
the induction of protein degradation by PIF was positively
correlated with AA release and subsequent conversion to 15(S)-
HETE (Smith et al, 1999). This process was blocked by
eicosapentaenoic acid, which also attenuated protein degradation
by PIF, both in vitro (Smith et al, 1999) and in vivo (Hussey and
Tisdale, 1999). These observations suggest that the formation of
eicosanoids from AA was important in PIF-induced protein
catabolism, mediated through the upregulation of the ubiquitin–
proteasome proteolytic pathway (Lorite et al, 2001). Despite the
importance of the ubiquitin–proteasome pathway, very little is
known about the intracellular signal transduction pathways
involved in gene expression. Although glucocorticoids are know
to activate the pathway by opposing the suppression of the
transcription of proteasome a-subunits by nuclear factor-kB (NF-
kB) (Du et al, 2000) other factors may be involved, since chronic
excessive glucocorticoid production, as occurs in Cushing’s
syndrome, does not increase proteasome expression (Ralliere
et al, 1997).
Arachidonic acid is released from cell membranes by the action
of phospholipases. PLA2 catalyses the release of fatty acid from the
sn-2 position of all membrane phospholipids with the formation of
lysophospholipids, while PLC hydrolyses the glycerophosphate
ester bond of a variety of phospholipids with the formation of DAG
and a phosphate monoester, which can be hydrolysed to AA by
DAG lipase (Figure 7). Quinacrine, a nonspecific inhibitor of PLA2,
was shown to attenuate PIF-induced proteasome activity, deter-
mined by the chymotrypsin-like enzyme activity, and protein
degradation, suggesting a role for PLA2 in this process.
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Figure 4 Effect of the concentration of PIF on the chymotrypsin-like
enzyme activity in C2C12 myotubes in the absence ( ) or presence of
genistein 30 (’), 100 (K) or 300 (T)mM (A) or 30 (&), 100 (’) or 300
(J)mM tryphostin A23 (B), where n¼ 9. Differences from the control are
indicated as a, Po0.05 and b, Po0.005, while differences in the presence of
the inhibitor are indicated as c, Po0.005 or d, Po0.05.
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Figure 5 (A) Effect of PIF concentration on the chymotrypsin-like
enzyme activity of the proteasome in C2C12 myotubes in the absence ( )
or presence (’) of 10mM PD98059. The experiment was repeated three
times (n¼ 9). Differences from the control are indicated as a, Po0.001,
while differences from those in the absence of inhibitor are indicated as b,
Po0.001. (B–D) Western blots of soluble extracts of C2C12 myotubes
treated with 0 (lanes 1 and 7); 1.0 (lanes 2 and 8); 2.1 (lanes 3 and 9); 4.2
(lanes 4 and 10); 10 (lanes 5 and 11) or 20 nM PIF (lanes 6 and 12) without
pretreatment (lanes 1–6) and after pretreatment for 2 h in the presence of
10mM PD98059 (lanes 7–12). Bands were detected using antibody to 20S
proteasome a-subunits (B), E214k(C) or b-tubulin (D).
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Proteolysis-inducing factor was shown to increase the expression
of iPLA2 at the same concentrations as those inducing the maximal
expression of 20S proteasome a-subunits and protein degradation.
The induction of iPLA2, proteasome expression and protein
degradation by PIF were completely inhibited by trifluroacetyl
arachidonic acid, an inhibitor of PLA2. This suggests that either
this derivative of AA is directly downregulating the expression of
iPLA2 or that AA itself is responsible for stimulating the expression
of iPLA2. These results confirm that iPLA2 is involved in PIF-
induced proteasome expression and protein degradation through
the release of AA from membrane phospholipids. The activation of
PLA2 has been shown to involve MAPK (Lin et al, 1993),
suggesting a relationship between the observed activation of
MAPK and PLA2 activation by PIF.
In addition to PLA2, PLC was also shown to be involved in
PIF-induced proteasome expression, as shown by the attenuation
of the effect using the PLC inhibitors U73122 and D609,
confirming the importance of the release of AA to the overall
process. D609 is a selective inhibitor of PC-specific PLC (Sauer
et al, 1984) and DAG derived from PC-PLC is suggested to provide
a positive feedback signal to PKC (Fallman et al, 1992),
which does not appear to cause downregulation of the enzyme
(Daiz-Laviada et al, 1990). TNF-a induction of ICAM-1 expression
in A549 cells involves the activation of PC-PLC, which induces
activation of PKCa and protein tyrosine kinase (Chen et al, 2001).
This suggests that the activation of PLC provides a signal for PKC
activation, as well as another source of AA. We have recently
shown PKC to be involved in PIF-induced proteasome expression
(unpublished results), possibly acting as a signal for NF-kB
activation (Vertegaal et al, 2000). TNF-a-induced activation of NF-
kB was inhibited by selective inhibitors of cytosolic PLA2
(Thommesen et al, 1998), suggesting that this pathway may also
be involved in NF-kB-activated gene expression. In addition, PC-
PLC has been shown to activate protein tyrosine kinase (Chen et al,
2001) and ERK (Toker, 1998). Both the tyrosine kinase inhibitors
genistein and tryphostin A23 attenuated PIF-induced proteasome
expression, suggesting a role for protein tyrosine kinase in this
process.
In mammalian cells, three parallel MAPK pathways have been
identified, which includes ERKs, p44 MAPK (ERK1) and p42
MAPK (ERK2), stress-activated protein kinase, c-Jun-NH2-term-
inal kinases and the p38 MAPK (Chang and Karin, 2001).
Extracellular signal-regulated kinases are activated by growth
factors acting via MAPK kinase kinase, (such as Raf) and MEKs are
involved in both cell proliferation and differentiation (Chang and
Karin, 2001). The pathway has been classically viewed to respond
to growth factors with the activation of tyrosine kinase receptors
acting through small G proteins, such as Ras, leading to the
activation of Raf, which then phosphorylates and activates MEK1
and MEK2, which in turn phosphorylate and activate ERK1 and
ERK2. The present study shows that PIF induces phosphorylation
of ERK1 and ERK2 at the same concentrations as those inducing
proteasome expression and that PD98059, a selective inhibitor of
MEK (Ku¨ltz et al, 1998), attenuated both the PIF-induced
activation or ERK1 and ERK2, and the induction of proteasome
expression. This suggests that PIF induces proteasome expression
through the MAPK pathway. The mechanism by which this occurs
is not known, but the MAPK/ERK pathway has been classically
viewed to respond to growth factors with the activation of tyrosine
kinase receptors acting through small G proteins, such as Ras
(Chang and Karin, 2001). The involvement of tyrosine kinase in
PIF induction of proteasome expression suggests the operation of a
similar pathway. These results provide some information on the
intracellular signalling pathways involved in the induction of
proteasome expression by PIF (Figure 7).
PIF has been shown to bind to a membrane receptor on skeletal
muscle (unpublished observations), although the nature of this
receptor and the relationship to PLA2 aret known. Although we
have only been able to demonstrate PIF production by cachexia-
inducing tumours (Cariuk et al, 1997), it may be important during
embryonic development. Proteolysis-inducing factor has been
shown to be expressed during the embryonic period E8–E9 in
mice, peaking during E8.5, a crucial stage in the patterning and
eventual development of skeletal muscle (Watchorn et al, 2001). It
seems that receptors for PIF required at this stage are still
expressed in adult skeletal muscle even in the absence of the
agonist. Although PIF production ceases in the adult, the peptide
chain, which is devoid of proteolytic activity (Todorov et al,
1996a), is still synthesised as the antimicrobial peptide dermicidin
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Figure 6 Western blot of active (phosphorylated) ERK1/2 and total
ERK1/2 (p44 and p42) (B) in soluble extracts of C2C12 myotubes treated
with 0 (lanes 1 and 7); 1.0 (lanes 2 and 8); 2.1 (lanes 3 and 9); 4.2 (lanes 4
and 10); 10 (lanes 5 and 11) or 20 nM PIF (lanes 6 and 12), without
pretreatment (lanes (1–6) or after pretreatment for 2 h in the presence of
10mM PD98059 (lanes 7–12).
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Figure 7 Signal transduction pathways involved in PIF activation of
proteasome expression. 15-LOX, 15-lipoxygenase; IP3, inositol 1, 4, 5-
trisphosphate.
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(Schittek et al, 2001) or as Y-P30, a neuronal survival peptide
(Cunningham et al, 2002). The acquisition by certain tumours of
the enzymes necessary to glycosylate this peptide chain leads to
PIF expression and breakdown of skeletal muscle.
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